Dr. Max Temnik is a serial entrepreneur with extensive experience in global business operations, acquisitions, negotiations, structuring, and execution. Since 2011, he has been involved in the scientific research and development of in-licensed isotope-selective modulation of the immune system, leading to the founding of Metallomix. 

Prior to his current venture, Dr. Temnik built a large real-estate development company. Under his leadership from 2002 to 2011, his company grew to employ over 3,000 people, generate annual revenue exceeding $1.5 billion, and manage construction projects worth more than $10 billion. During this period, Dr. Temnik held various executive and board positions, took on operational C-level roles, and spearheaded company expansion into Eastern Europe, Switzerland, Montenegro, Turkey, and the United Kingdom.